MX2023000099A - Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes. - Google Patents

Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes.

Info

Publication number
MX2023000099A
MX2023000099A MX2023000099A MX2023000099A MX2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A
Authority
MX
Mexico
Prior art keywords
glucokinase
treating diabetes
nucleic acids
modified insulin
same
Prior art date
Application number
MX2023000099A
Other languages
English (en)
Spanish (es)
Inventor
Cenzano Veronica Jimenez
Tubert Maria Fatima Bosch
Nachi Gupta
Weiran Shen
Martinez Miquel Garcia
Original Assignee
Kriya Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kriya Therapeutics Inc filed Critical Kriya Therapeutics Inc
Publication of MX2023000099A publication Critical patent/MX2023000099A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023000099A 2020-07-03 2021-07-02 Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes. MX2023000099A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063047965P 2020-07-03 2020-07-03
US202063054162P 2020-07-20 2020-07-20
US202063067264P 2020-08-18 2020-08-18
US202163141918P 2021-01-26 2021-01-26
US202163188778P 2021-05-14 2021-05-14
PCT/US2021/040366 WO2022006551A2 (en) 2020-07-03 2021-07-02 Modified insulin and glucokinase nucleic acids for treating diabetes

Publications (1)

Publication Number Publication Date
MX2023000099A true MX2023000099A (es) 2023-04-20

Family

ID=79317842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000099A MX2023000099A (es) 2020-07-03 2021-07-02 Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes.

Country Status (10)

Country Link
US (2) US20240279300A1 (cg-RX-API-DMAC7.html)
EP (1) EP4176060A4 (cg-RX-API-DMAC7.html)
JP (2) JP7837963B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230087436A (cg-RX-API-DMAC7.html)
CN (1) CN116234904A (cg-RX-API-DMAC7.html)
AU (1) AU2021300450A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174156A1 (cg-RX-API-DMAC7.html)
IL (1) IL299545A (cg-RX-API-DMAC7.html)
MX (1) MX2023000099A (cg-RX-API-DMAC7.html)
WO (1) WO2022006551A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299545A (en) * 2020-07-03 2023-02-01 Kriya Therapeutics Inc Different insulin and glucokinase nucleic acids for the treatment of diabetes
US20250288693A1 (en) * 2022-04-29 2025-09-18 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes
CN122249241A (zh) * 2023-11-01 2026-06-19 克里雅疗法股份有限公司 用于治疗糖尿病的aav介导的胰岛素和葡萄糖激酶基因疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI345587B (en) * 2003-06-17 2011-07-21 Sembiosys Genetics Inc Methods for the production of insulin in plants
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
EP3242945B1 (en) * 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
IL299545A (en) * 2020-07-03 2023-02-01 Kriya Therapeutics Inc Different insulin and glucokinase nucleic acids for the treatment of diabetes
US20250288693A1 (en) * 2022-04-29 2025-09-18 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes

Also Published As

Publication number Publication date
WO2022006551A3 (en) 2022-02-03
JP2026034616A (ja) 2026-02-27
EP4176060A2 (en) 2023-05-10
AU2021300450A1 (en) 2023-03-02
EP4176060A4 (en) 2024-08-07
CA3174156A1 (en) 2022-01-06
US20240279300A1 (en) 2024-08-22
IL299545A (en) 2023-02-01
KR20230087436A (ko) 2023-06-16
US20260139024A1 (en) 2026-05-21
WO2022006551A2 (en) 2022-01-06
JP7837963B2 (ja) 2026-03-31
CN116234904A (zh) 2023-06-06
JP2023542241A (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
WO2022006551A3 (en) Modified insulin and glucokinase nucleic acids for treating diabetes
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
PH12020550757A1 (en) Primate retinal pigment epithelium cell-specific promoter
MX2023001394A (es) Genes del factor viii optimizados.
PH12020550766A1 (en) Synp61, a primate retinal pigment epithelium cell-specific promoter
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
WO2022046935A3 (en) Methods and compositions for treating glioblastoma
AR105822A1 (es) Análogos de insulina
WO2020163743A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
MX2021003261A (es) Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.
NZ603028A (en) Tfpi inhibitors and methods of use
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
PH12019502522A1 (en) Oncolytic virus and method
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
WO2022195074A3 (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
NZ752941A (en) Frataxin expression constructs
MX2016012558A (es) Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo.
PH12020551191A1 (en) Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector
ZA202304029B (en) Cxcl9 and variants thereof for immunotherapy of cancer diseases
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
PH12017502323B1 (en) Novel xylanase
PH12022550270A1 (en) Method for treating muscular dystrophy by targeting lama1 gene
MY182443A (en) Method of producing lipid
MX2024004333A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
IN2014DE00902A (cg-RX-API-DMAC7.html)